Medical Center

2300 Ramsey St.
Fayetteville NC 28301

255

Veterans Administration

In Reply Refer To: 565/115

28 JAN 1988

Director
Office of Nuclear Materials Safety and Safeguards
U. S. Nuclear Regulatory Commission
Washington, D. C. 20555

88 FEB 8 A10:06

THRU: Mid-Atlantic Regional Director (10BA2/115)
VA Central Office
Washington, D. C. 20020

SUBJ: Request for Amendment to NRC Byproduct Materials License
License # 32-13654-01
Amendment No. 24
Licensee--Veterans Administration Medical Center
2300 Ramsey Street
Fayetteville, North Carolina 28301
Expiration Date: April 30, 1991

1. The purpose of this amendment is to add Jerome A. Olack, M. D. to the facility's license.

2. A copy of the NRC Byproduct Materials License on which Dr. Olack was an authorized user is enclosed.

3. Your favorable consideration is appreciated.

A. G. BRANCH
Director

Enclosure

2/2/88

JAMES W. FLETCHER, M.D.
Director, Nuclear Medicine Service (115)
Veterans Administration
Washington, DC 20420

FEE EXEMPT

8803080194 880219
REG2 LIC30
32-13654-01 PDR

Official Copy

MATERIALS LICENSE

Amendment No. 27

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93 – 438), and Title 10, ode of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Jameson Memorial Hospital Department of Radiology and Pathology 2. 222 West Leasure Avenue New Castle, Pennsylvania 16101	In accordance with application dated February 12, 1986 3. License number 37-01146-03 is amended in its entirety to read as follows: 4. Expiration date August 31, 1988 5. Docket or Reference No. 030-02977

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 2 curies of each byproduct material authorized in Subitem 6.B.
C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. As necessary for uses authorized in Subitem 9.C.
D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. Any radiopharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. As necessary for uses authorized in Subitem 9.D.
E. Any byproduct material listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. Any sealed source listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. 2000 millicuries total for sources authorized in Subitem 6.E.
F. Any byproduct material listed in Section 31.11(a) of 10 CFR 31	F. Prepackaged kits	F. 3 millicuries of each byproduct material authorized in Subitem 6.F.

8611260349 6PP

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 37-01146-03
Docket or Reference number: 030-02977
Amendment No. 27

(6., 7., and 8. continued) CONDITIONS

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
G. Xenon 133	G. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA	G. 200 millicuries
H. Uranium (depleted in the isotope Uranium 235)	H. Cadmium plated metal	H. 160 kilograms
I. Gadolinium 153	I. Sealed Source (Lunar Model GD series)	I. Not to exceed 1.5 curies each, 3 curies total

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100, Title 10, Code of Federal Regulations.
B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
E. Any procedure listed in Group VI of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
F. In vitro studies.
G. Blood flow and pulmonary function studies.
H. For use as shielding in a linear accelerator.
I. For use in Lunar Model DP3 or DP4 Bone Mineral Analyzer for diagnosis of patients.

CONDITIONS

10. Licensed material shall be used only at 222 West Leasure Avenue, New Castle, Pennsylvania.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
37-01146-03

Docket or Reference number
030-02977

Amendment No. 27

(continued) CONDITIONS

11. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Eugene Isidro, M.S.	Group I In vitro studies Gadolinium 153 sealed sources for diagnosing bone maladies
Joseph P. Concannon, M.D.	Groups IV, V and VI Depleted uranium for shielding Gadolinium 153 sealed sources for diagnosing bone maladies
Thomas Bauman, M.D.	Groups I, II, III and VI In vitro studies Xenon 133 Iodine 131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma Depleted uranium for shielding Gadolinium 153 sealed sources for diagnosing bone maladies
James. M. Hughes, M.D.	Group VI In vitro studies Depleted uranium for shielding Gadolinium 153 sealed sources for diagnosing bone maladies
Jerome A. Olack, M.D.	Groups I, II and III In vitro studies Xenon 133 Iodine 131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma Gadolinium 153 sealed sources for diagnosing bone maladies
Adele Lipari, D.O.	Groups I, II and III Xenon 133 Iodine 131 for treatment of hyperthyroidism and cardiac dysfunction Gadolinium 153 sealed sources for diagnosing bone maladies
Susan M. Geletka, M.D.	Groups I, II and III Xenon 133 Iodine 131 as iodide for thyroid uptake studies, treatment of hyperthyroidism and cardiac dysfunction Gadolinium 153 sealed sources for diagnosing bone maladies

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
37-01146-03

Docket or Reference number
030-02977

Amendment No. 27

(11. continued)

	CONDITIONS
Donna Sefczek, M.D.	Groups I, II and III In vitro studies Iodine 131 for treatment of hyperthyroidism and cardiac dysfunction Xenon 133 Gadolinium 153 sealed sources for diagnosing bone maladies
Robert Sefczek, M.D.	Groups I, II and III In vitro studies Iodine 131 for treatment of hyperthyroidism and cardiac dysfunction Xenon 133 Gadolinium 153 sealed sources for diagnosing bone maladies
Gerald Medwick, D.O.	Group VI Depleted uranium for shielding Gadolinium 153 sealed sources for diagnosing bone maladies

12. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of 10 half-lives.

B. Before disposal as normal waste, radioactive waste shall be surveyed to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated.

C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

13. For a period not to exceed 60 days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

A. Has the prior written permission of the hospital's Administrator and Radiation Safety Committee, and

B. Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and

C. Performs only those procedures which the physician is specifically authorized to perform pursuant to a license issued by the Nuclear Regulatory Commission.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
37-01146-03

Docket or Reference number
030-02977

Amendment No. 27

(13. continued) CONDITIONS

The licensee shall maintain for inspection by the Commission copies of the written permission specified in A. above and of the licenses specified in B. and C. above for a period of 5 years from the date permission is granted under A. above.

14. The licensee may use the Calicheck device for doing linearity tests of its dose calibrator provided it follows the procedures in the Calcorp, Inc., Manual dated March 2, 1982.

15. A. The sealed source or detector cell specified in Item 7.I shall be tested for leakage and/or contamination at intervals not to exceed one year. Any source received from another person which is not accompanied by a certificate indicating that a test was performed within 6 months before the transfer shall not be put into use until tested.

B. Any sealed source or detector cell in storage and not being used need not be tested. When the source or detector cell is removed from storage for use or transfer to another person, it shall be tested before use or transfer.

C. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie or more of removable contamination, the source or detector cell shall be removed from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. A report shall be filed within 5 days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region I, ATTN: Chief, Nuclear Materials Safety and Safeguards Branch, 631 Park Avenue, King of Prussia, Pennsylvania 19406. The report shall specify the source involved, the test results, and corrective action taken. Records of leak test results shall be kept in units of microcuries and shall be maintained for inspection by the Commission. Records may be disposed of following Commission inspection.

D. The licensee is authorized to collect leak test samples for analysis by Krishnadas Banerjee, Ph.D. or tests for leakage and/or contamination shall be performed by persons specifically licensed by the Commission or an Agreement State to perform such services.

(continued) CONDITIONS

16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated June 29, 1983
B. Letter dated February 12, 1986
C. Letter dated June 13, 1986
D. Letter dated July 22, 1986



For the U.S. Nuclear Regulatory Commission

Date SEP 05 1986

By _____
Nuclear Materials Safety and
Safeguards Branch, Region I
King of Prussia, Pennsylvania 19406